What is the clinical evidence from this study?

Study design: Other. Population: Healthy donors (in vitro platelet study). Intervention: dBcAMP or PGE1 vs. Control (no dBcAMP or PGE1). Primary outcome: Formation of oxygenated products of arachidonic acid (thromboxane A2, thromboxane B2, and malonaldehyde) after thrombin addition.

What question did this study set out to answer?

This research aims to investigate how cyclic adenosine monophosphate (cAMP) affects the availability of arachidonic acid in human platelets.

March 1, 1977Journal of Clinical InvestigationOpen Access

Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.

View Full Paper

Ask AI

Bookmark

Key result

Incubation of human platelets with dBcAMP or PGE1 before thrombin addition blocks the formation of oxygenated products of arachidonic acid by inhibiting its hydrolysis from phospholipids.

Why the study?

Does incubation with dBcAMP or PGE1 prevent thrombin-induced prostaglandin synthesis in human platelet suspensions?

Population

Washed human platelet suspensions

Comparison

Incubation with dibutyryl cyclic adenosine… vs Thrombin addition without prior incubation, or…

Design

Preclinical

Authors

MMMark S. MinkesWashington University in St. Louis NSN StanfordWashington University in St. Louis MMM MWashington University in St. Louis

Discussion

Member takes

Implication

Does not support clinical antiplatelet changes; leaves open in vivo validation of cAMP/PGE1 effects on platelet activation.

Key Points

This research aims to investigate how cyclic adenosine monophosphate (cAMP) affects the availability of arachidonic acid in human platelets.
Washed human platelets were treated with thrombin to activate phospholipase and release arachidonic acid.
Platelets were incubated with dibutyryl cyclic adenosine 3',5'-monophosphate (dBcAMP) or prostaglandin E1 (PGE1) prior to thrombin exposure.
The study assessed the impact of these treatments on prostaglandin and thromboxane synthesis.
Thrombin-induced formation of thromboxane A2 and its metabolites was inhibited by dBcAMP or PGE1.
Direct addition of arachidonic acid negated the inhibitory effects of dBcAMP or PGE1 on prostaglandin production.
Higher concentrations of thrombin (0.05-2 U/ml) were necessary for prostaglandin synthesis compared to serotonin release (0.02-0.1 U/ml).

Structured PICO

Does incubation with dBcAMP or PGE1 prevent thrombin-induced prostaglandin synthesis in human platelet suspensions?

Population

In vitro study using washed human platelets obtained from healthy donors who had abstained from medication for at least 2 weeks.

Intervention

Incubation with dibutyryl cyclic adenosine 3',5'-monophosphate (dBcAMP) or prostaglandin E1 (PGE1) before thrombin addition

Comparator

Thrombin addition without prior incubation, or direct addition of arachidonic acid

Outcome

Formation of oxygenated products of arachidonic acid (thromboxane A2, thromboxane B2, and malonaldehyde)surrogate

Agents that elevate platelet cAMP levels inhibit the hydrolysis of arachidonic acid from platelet phospholipids, demonstrating that prostaglandin synthesis can be partially dissociated from platelet aggregation and release.

Limitations

In vitro study design
The exact mechanism by which dBcAMP inhibits arachidonic acid hydrolysis remains to be elucidated
Results conflict with some previous findings regarding direct inhibition of cyclo-oxygenase by cAMP

Cite This Study

Minkes et al. (1977) studied Healthy donors (in vitro platelet study). dBcAMP or PGE1 vs. Control (no dBcAMP or PGE1) was evaluated on Formation of oxygenated products of arachidonic acid (thromboxane A2, thromboxane B2, and malonaldehyde) after thrombin addition. Incubation of human platelets with dBcAMP or PGE1 before thrombin addition blocks the formation of oxygenated products of arachidonic acid by inhibiting its hydrolysis from phospholipids.

synapsesocial.com/papers/6a6c185201245da06ecbb25a https://doi.org/10.1172/jci108659

View Full Paper

Ask AI

Bookmark

Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider